Drug Delivery Disposition and Dynamics
Other research themes
Our latest news
The Travelling Award will provide Dr Cao with the unique opportunity to travel to Colorado, USA, to attend the Keystone Symposium – Adipose tissue: energising good fat.
A drug delivery platform developed by Monash University researchers in partnership with PureTech Health plc has shown for the first time in humans that a drug that currently must be injected due to breakdown in the liver after oral administration,
A team of MIPS mRNA researchers has partnered with the Children’s Medical Research Institute to combine mRNA delivery with viral gene delivery to treat metabolic liver disease in infants and children.
The two vaccine candidates were created by researchers at the Doherty Institute and MIPS and are distinct from existing vaccines in use around the globe.
Monash University researchers have harnessed a new drug delivery technology to allow the oral administration of buprenorphine (BUP), a drug used for severe pain management and opioid replacement therapy. At present BUP cannot be administered in a
Deemed a global health crisis, Gram-negative bacteria can cause life-threatening infections including pneumonia, bloodstream infections, urinary tract infections, peritonitis and meningitis.
Melbourne researchers are calling on healthy people aged 18-70 living in Victoria to roll up their sleeves for a Phase 1 clinical trial of two Melbourne-made COVID-19 vaccines.
A MIPS research initiative aimed at preventing postpartum haemorrhage, the leading cause of maternal mortality globally, has received just under $500,000 from the Commonwealth Government’s Accelerating Commercialisation fund.
Drug researchers from the Monash Institute of Pharmaceutical Sciences have published more than 400 new protein targets for peroxide antimalarials, the most advanced form of medicine currently being used to treat malaria infections caused by the